1571

The question does not provide enough information to provide a conclusive answer. The treatment for this type of product has to be decided on a case by case basis.  Relevant aspects to consider in this decision include but are not necessarily limited to:·       What is the exposure to biometrical risks?·       Has the look-through approach to be applied to the investment?·       What is the degree of certainty regarding level and timing of payments?A possible result of the assessment could be that the investment has to be included in the calculation of the capital requirement for type 2 equities which include·       Alternative investments.·       All assets other not covered in the interest rate risk, property risk or spread risk sub-module·       Assets and indirect exposures referred to in Article 84(1) and (2) of Commission Delegated Regulation (EU) 2015/35 where a look-through approach is not possible and the insurance or reinsurance undertaking does not make use of the provisions in Article 84(3).